Concepedia

Author

Yves Dutronc

Eli Lilly (United States)ORCID

Also Known As

Dutronc, Yves, Y DUTRONC, Y Dutronc, Y. Dutronc, Yves Dutronc

92

Publications

2.7K

Citations

27

H-Index

43

Concepts

All Affiliations

Eli Lilly (United States)Yale UniversityStanford UniversityUniversity of California, IrvineKyorin University
YD

About

Yves Dutronc is an author at Eli Lilly (United States) specializing in medicine, dermatology, and rheumatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

447

2

Allergy

2

2

107

3

Engineering

1

1

159

4

Public Health

1

1

20

5

Allergy Medicine

1

1

41

Yves Dutronc

×

30

Publications

2.3K

Citations

24

H-Index

YearCitations

Modulation of CD1d-restricted NKT cell responses by using <i>N-</i> acyl variants of α-galactosylceramides

Karl O. A. Yu, Jin S. Im, Alberto Molano,

Proceedings of the National Academy of Sciences

2005

323

Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells

Brian K. Bonish, D. Jullien, Yves Dutronc,

The Journal of Immunology

2000

219

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study

Kristian Reich, Andreas Pinter, J.‐P. Lacour,

British Journal of Dermatology

2017

185

Prediction of Survival for Patients With Bullous Pemphigoid

P. Joly, Jacques Bénichou, Catherine Lok,

Archives of Dermatology

2005

163

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Eric L. Simpson, Robert Bissonnette, Lawrence F. Eichenfield,

Journal of the American Academy of Dermatology

2020

159

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair,

American Journal of Clinical Dermatology

2023

131

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Brett King, Justin Ko, Seth Forman,

Journal of the American Academy of Dermatology

2021

111

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

C. Paul, C.E.M. Griffiths, P.C.M. van de Kerkhof,

Journal of the American Academy of Dermatology

2018

99

The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials

Kathleen W. Wyrwich, Helen Kitchen, S.L. Knight,

British Journal of Dermatology

2020

94

“‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata

Natalie V. J. Aldhouse, Helen Kitchen, S.L. Knight,

Journal of Patient-Reported Outcomes

2020

91

Page 1